Skip to content

Advertisement

Volume 17 Supplement 1

Taurine – a wonder molecule. Proceedings of the 17th International Taurine Conference

  • Review
  • Open Access

Characterization of taurine as anti-obesity agent in C. elegans

†Contributed equally
Journal of Biomedical Science201017 (Suppl 1) :S33

https://doi.org/10.1186/1423-0127-17-S1-S33

©  Lee et al; licensee BioMed Central Ltd. 2010

  • Published:

Abstract

Background

Taurine plays an important role in reducing physiological stress. Recent studies indicated that taurine may serve as an anti-obesity agent at the cellular level. This study characterizes taurine’s potential anti-obesity function in C. elegans, which have become a popular in vivo model for understanding the regulatory basis of lipid biosynthesis and deposition.

Methods

Two strains of C. elegans were raised on a normal or high-fat diet: N2 (normal) and RB1600, a mutant in tub-1 that serves as a tubby homologue and functions parallel to the 3-ketoacyl-CoA thiolase gene (kat-1) in regulating lipid accumulation. Taurine’s effect on lipid deposition was characterized according to assays of Sudan black B staining, triglyceride content measurement, food consumption, and mobility comparison.

Results

When N2 was treated with taurine after the culture in the high-fat media, the worms showed lower lipid accumulation in the assays of the Sudan black B staining and the triglyceride quantification. The anti-obesity effect was less evident in the experiment for RB1600. When the amount of taurine was increased for the high-fat-diet-treated N2 strain, fat deposition decreased and mobility increased in a dose-dependent manner. In the food consumption assays, taurine did not cause a significant change in food intake.

Conclusions

Taken together, these results strongly imply that taurine plays an important role in reducing fat deposition by modulating cellular pathways for lipid accumulation and stimulating mobility, but not the pathways for lipid biosynthesis and food intake.

Keywords

  • Taurine
  • Lipid Accumulation
  • Lipid Biosynthesis
  • Triglyceride Content
  • Nematode Growth Medium

Background

Taurine, or 2-aminoethanesulfonic acid, is the major component of bile and is present in many types of animal tissues, including in the gall bladder, blood vessels, eyes, and lower intestine. Although taurine is less known as an amino acid, it is commonly used as a functional component of various types of health drinks. It plays a vital role in adjusting physiological pathways in antioxidation and detoxification. Recent studies indicated that taurine deficiency is associated with persistent obesity, which can be prevented by dietary taurine supplementation [1, 2]. This study tested taurine’s anti-obesity potential with C. elegans, which are frequently used as a tractable system in current biomedical researches [3, 4].

C. elegans is a very useful animal system in unearthing crucial biological mechanisms that are readily applicable to many higher-level organisms, including humans [5, 6]. Indeed, many recently discovered biological pathways of C. elegans have been proven analogous to those of mammals, despite its relatively simple body structure [7–9]. Its short generation period of three days enables researchers to perform a drug screen with a time advantage over other test systems, including rodents. Unlike mammals, though, C. elegans lacks leptin-like molecules and their receptor, which participate in regulating fat storage. This makes C. elegans attractive to many researchers who are mass-screening taurine’s potential as an anti-obesity agent, since C. elegans should provide genuine biochemical information on fat storage and utilization that is independent of the hormonal inhibition of food intake. Under certain circumstances, C. elegans serves as a tractable system of studying taurine’s effect on obesity and fat accumulation, and thus, its anti-obesity potential.

Lipid accumulation involves complex processes of lipid biosynthesis, transport, and storage [10–13]. Lipid biosynthesis is mainly controlled by sterol regulatory element-binding proteins (SREBPs). In mammals, stored fat is consumed according to various transcriptional, translational, and post-translational regulation processes, as in mammals. The SREBP cleavage-activating proteins (SCAPs) are believed to play an important role in activating SREBPs before the SREBPs’ transport into the nucleus. The majority of mammalian lipases are homologous to those in C. elegans. In C. elegans, SBP-1, an SREBP homologue, regulates fatty acid homeostasis by modulating the expression of various lipogenic enzymes.

In C. elegans, the gene products of tub-1 are believed to manage lipid accumulation in cooperation with those of kat-1, which govern fatty acid beta-oxidation [14–17]. The tub-1 mutants show an excessive obese phenotype especially under an impaired kat-1 gene. The level of fatty acyl-CoA is very important in controlling the rate of beta-oxidation. Its level is rigorously controlled by carnitine acyltranferase, which transports acyl-CoA and its derivatives into the mitochondrion [18–20]. The enzymatic activity is governed by malonyl-CoA. With increased levels of acetyl-CoA and citrate, however, beta-oxidation decreases in a negative feedback.

This study characterized taurine as an anti-obesity agent in C. elegans that were fed a high-fat diet. The strains of N2, both the normal and RB1600, that mutated in the tub-1 gene were tested under four classes of experiments. The worms were analyzed using Sudan black B staining, food intake assay, triglyceride measurement, and mobility assessment.

Methods

Worm culture and taurine treatment

C. elegans were grown on standard nematode-growth media that contained high or normal content of cholesterol as 25.0 or 12.5 μM, respectively. During each experiment, the worms were grown on the nematode growth media (NGM) that contained E. coli OP50 as a food source. The taurine-containing media were prepared by smearing an appropriate amount of taurine stock solution onto the media. The stock of E. coli OP50 was prepared by culturing it overnight in an LB medium until concentrated particles were formed. The quantity of OP50 in the media was adjusted depending on the initial worm input and the duration of the worm culture.

Sudan black B staining

The anti-obesity effect of taurine was studied via microscopy on stained worms. Individual worms were fixed and stained with Sudan black, which stains lipid stores into opaque blue. For the staining, the worms were removed from the culture plates and were starved for 6 h. After they were washed in M9 media, they were fixed with 1% paraformamide in M9. Then they were subjected to three freeze-thaw cycles and dehydrated in 95% ethanol. The staining was performed in 70% ethanol saturated with Sudan black B.

Lipid content measurement

The lipid contents were quantitated by measuring the triglyceride content of the worms that were treated under taurine or taurine-free conditions. The worms were thoroughly washed in TBS and homogenized and sonicated in a Triglyceride Assay Buffer (TAB) and the triglyceride content was assessed using a BioVision triglyceride assay kit (Mountain view, CA, USA). After brief centrifugation, the samples were diluted to a final volume of 50μl/well. Following the dilution of the samples in two microliters of lipase, the samples were incubated for 20 min at room temperature to convert their triglycerides into glycerol and fatty acid. The optical density of each of the incubated samples was measured at 570 nm for the colorimetric assay in a microplate reader. The calculations were made by subtracting the background value derived from the 0 triglyceride standard from all the sample readings. The triglyceride concentration (nmol/μl) was calculated according to the formula [TC] = Ts (nmol) / Sv (μl) [Ts: amount of triglycerides from the standard curve, and Sv: sample volume (before dilution) in the sample wells].

Food consumption assay

Worms were treated on taurine or taurine-free media for 12 hours; then, they were subjected either to fast or to copious feeding with OP50 for 6 h on NGM media. Twenty worms of 1-day-old were transferred onto NGM plates covered with lawn of identical amount of OP50 (9 X 109 cfu). The time taken for total intake of the food input was measured and compared among the treatment and genotypes.

Mobility assay

After the worms’ culture on the tunicamycin-containing media, they were further grown on taurine-containing media. The moving distances of the worms that were treated with various taurine concentrations were visually compared. The difference in the mobility of the taurine-treated and the non-taurine-treated worms was observed in a light box.

Results

Several experiments were performed to examine the effect of taurine on fat accumulation in the normal and tubby strains of C. elegans. Throughout the various taurine treatments, differences in the lipid accumulation were evident both qualitatively and quantitatively under Sudan black staining, food consumption assay, fatty acid quantification, and mobility comparison analysis.

Fat accumulation decreased under taurine treatment via Sudan black staining

The anti-obesity effect of taurine was studied under a microscope. Fig. 1 shows taurine’s effect on lipid storage, as manifested via Sudan black B staining, after the worms were treated for 24 h with two different taurine concentrations. When cultured on a high-fat diet, the worms appeared to accumulate excess triglyceride in separate opaque spots that were highly noticeable in the intestinal and hypodermal tissues. No substantial difference appeared in the fat stores of the worms that were treated with a normal diet (data not shown), but notable differences emerged among the worms that were treated with a high-fat diet followed by taurine treatment. Taurine’s effect of reducing lipid storage was definite in the wild-type strain of N2 (upper panel, Fig. 1), but its effect was minimal or insignificant for tub-1, the lipid storage mutant (lower panel).
Figure 1
Figure 1

Sudan black B staining of taurine-treated worms C. elegans were treated with taurine for 24 h and its effect on lipid storage was observed by Sudan black B staining. The taurine’s effect on reduction of lipid accumulation was significant in the wild type strain of N2. However, the effect of taurine was minimal or insignificant for the lipid storage mutant, tub-1.

The triglyceride level was low in taurine-treated worms

In addition to a visual comparison of the lipid droplet that was formed in the Sudan black B staining experiment, this experiment assessed the total amount of triglycerides in C. elegans. The measurement that was performed in this experiment genuinely referred to the lipid biosynthesis in the worms. The triglyceride content was shown to correspond to those in the experiment and to the dose-dependent anti-obesity effect of taurine (Fig. 2). In the absence of taurine, the normal (N2) strains sensitively responded to the high-fat diet via fat accumulation in a dose-dependent manner. Unlike in the staining experiment, however, the tub-1 mutant positively responded to taurine by showing a lower triglyceride content under the taurine treatment. The inconsistency between the staining and the quantitation results in the tubby worms implies that taurine may work in the stage of fat biosynthesis rather than in the stage of fat accumulation.
Figure 2
Figure 2

Triglyceride content measurement The high fat grown N2 worms positively responded to the taurine treatment in a dose-dependent manner when the triglyceride content was measured as described in Methods. The response of tub-1, however, showed no significance compared to N2.

The taurine treatment did not alter the food consumption assay of the worms

No considerable difference was seen between the worms that were treated with taurine and the worms in the taurine-free conditions. Fig. 3 shows little or no difference between the taurine-treated worms and the non-taurine-treated control, although the starved and the well-fed worms significantly differed in the length of time of their complete food consumption. This observation indicates that taurine may not affect worms’ craving for food, and thus, the potential anti-obesity function of taurine does not stem from the suppression of food ingestion.
Figure 3
Figure 3

Food consumption assay The time taken for the total consumption of OP50 was compared among the taurine treatments. A significant difference was observed between starved (A) and well-fed (B) worms; however, no significance was noticed between the taurine treatments within the strain. The x-axis refers to the time (min) taken for a total consumption of food.

The worms became active under taurine treatment

After the tunicamycin-treated worms were further grown on taurine-containing media, the extents of the worms’ movement after various treatment concentrations were visually compared (Fig. 4). The visual comparison of the worms’ tracks revealed that the taurine-treated worms travelled longer distances than the non-taurine-treated control (Table 1.). The positive effect of taurine on mobility may contribute to the reduction of lipid accumulation in C. elegans. Taurine’s effect was more pronounced when the worms were treated with more taurine.
Table 1

Motility comparison assay

[Taurine]

Strain

0

1

5

10 (μg/ml)

N2

d0

d++

d+++

d+++

tub-1

d0

d+

d0

d+

Worms were grown on taurine-containing or free media. The distance of worm’s movement was compared among the taurine treatments. “do” refers to the distance the worms moved on the taurine–free media. “+” denotes an approximate 10% increase in mobility according to the length of path left on the media.

Discussion

Using C. elegans systems, this study tested taurine’s potential as an anti-obesity agent by helping reduce lipid accumulation in cells. Taurine significantly decreased fat storage depending on its concentration. Without negatively affecting food intake, taurine showed substantially reduced fat accumulation and increased activity, which matched the reduction of lipid storage under its treatment.

Complex cellular mechanisms coordinate the equilibrium between lipid utilization and accumulation [21–23]. Being critical for the utilization of stored lipids, beta-oxidation converts fatty acids to acetyl co-A and requires the release of fatty acids from triacylglycerides by lipases [24–27]. The increased activity of the worms after the taurine treatment strongly suggests that the lesser accumulation of fat was due to the higher level of beta-oxidation from the taurine-enhanced activities of the C. elegans.

One of the findings in this study is that taurine had only a minor anti-obesity effect on the tub-1 mutant, unlike on the normal strain. Unlike the wild type, the tubby mutants are known to store more fat due to their inability to control excessive transport to fat storage tissues or to react properly to metabolic signals from ciliated neurons [28, 29]. Thus, taurine’s potential anti-obesity effect is not applicable to the lipid accumulation stage or is independent of the pathways where tub-1 is involved.

The Sudan black B staining and triglyceride assays showed inconsistent results concerning the tub-1 mutants in response to taurine. That is, the Sudan black B staining did not show noticeable sensitivity to taurine application, but the triglyceride content measurements showed a significant difference between the taurine-free and the taurine-treated worms. These inconsistent results strongly indicate that the taurine had a more immediate impact on lipid deposition than on fat synthesis.

As in mammals, C. elegans accumulates fat both from its diet and via de novo biosynthesis, and stores lipids in subcellular compartments. Not enough information is available, however, on how C. elegans acquires, synthesizes, uses, and stores lipids, but the consistent results of this study indicate that taurine diminishes lipid storage by enhancing physical activities, rather than by reducing food uptake. Despite these data, the mechanism behind the subcellular targeting and sequestration that dictate the magnitude and numbers of these deposits remains to be determined.

Conclusions

In summary, this study showed that taurine affects lipid deposition in a dose-dependent manner. Reduced lipid storage was evident in the wild-type worms but not in the tub-1 mutants. Unlike tub-1, N2 positively responded to taurine according to its triglyceride content assay. The increased mobility with the taurine treatment may contribute to reduced lipid deposition via enhanced lipid consumption. An additional study is necessary to clarify the potential mechanisms for the fat storage reduction. A new study may be rewarding in finding a definite agent that would modulate tub-1/kat-1 and sbp-1 molecules. Collective treatment of these molecules with taurine is a good way to generally cope with obesity.

Notes

List of abbreviations used

SREBP: 

sterol regulatory element-binding protein

TAB: 

triglyceride assay buffer

kat-1: 

3-ketoacyl-CoA thiolase-1

NGM: 

nematode growth media

Declarations

Acknowledgements

This article has been published as part of Journal of Biomedical Science Volume 17 Supplement 1, 2010: Proceedings of the 17th International Meeting of Taurine. The full contents of the supplement are available online at http://www.jbiomedsci.com/supplements/17/S1.

We appreciate Dong-A Pharmaceutical Company for providing materials including taurine. We also thank the Molecular Biology Lab students for confirming the data by repeating the experiments in this study.

Authors’ Affiliations

(1)
Department of Life Sciences, University of Seoul, Dongdaemun-Gu, Seoul, 130-743, Korea
(2)
College of Agriculture and Science, Chungnam National University, Yuseong, Daejeon, 305-764, Korea

References

  1. Tsuboyama-Kasaoka N, Shozawa C, Sano K, Kamei Y, Kasaoka S, Hosokawa Y, Ezaki O: Taurine (2-aminoethanesulfonic acid) Deficiency Creates a Vicious Circle Promoting Obesity. Endocrinology. 2006, 147: 3276-3284. 10.1210/en.2005-1007.View ArticlePubMedGoogle Scholar
  2. Zhang M, Bi LF, Fang JH, Su XL, Da GL, Kuwamori T, Kagamimori S: Beneficial effects of taurine on serum lipids in overweight or obese non-diabetic subjects. Amino acids. 2004, 26: 267-271.PubMedGoogle Scholar
  3. Chiang SH, MacDougald OA: Will fatty worms help cure human obesity?. Trends in Genetics. 2003, 19: 523-525. 10.1016/j.tig.2003.08.002.View ArticlePubMedGoogle Scholar
  4. McKay RM, McKay JP, Avery L, Graff JM: C elegans: a model for exploring the genetics of fat storage. Dev Cell. 2003, 4: 131-142. 10.1016/S1534-5807(02)00411-2.PubMed CentralView ArticlePubMedGoogle Scholar
  5. Wagner GP: The developmental genetics of homology. Nat Rev Genet. 2007, 8: 473-479. 10.1038/nrg2099.View ArticlePubMedGoogle Scholar
  6. Leung KF, Baron R, Seabra MC: Thematic review series: Lipid posttranslational modifications. J Lipid Res. 2006, Geranylgeranylation of Rab GTPases, 47: 467-475. 10.1194/jlr.R500017-JLR200.Google Scholar
  7. Ashrafi K: Obesity and the regulation of fat metabolism. WormBook. 2007, 1-20.Google Scholar
  8. Watts JL, Browse J: Genetic dissection of polyunsaturated fatty acid synthesis in Caenorhabditis elegans. Proc Natl Acad Sci U. S. A. 2002, 99: 5854-5859. 10.1073/pnas.092064799.PubMed CentralView ArticlePubMedGoogle Scholar
  9. Suh JM, Zeve D, McKay R, Seo J, Salo Z, Li R, Wang M, Graff JM: Adipose is a conserved dosage-sensitive antiobesity gene. Cell Metab. 2007, 6: 195-207. 10.1016/j.cmet.2007.08.001.PubMed CentralView ArticlePubMedGoogle Scholar
  10. Falk M, Zhang Z, Rosenjack J, Nissim I, Daikhin E, Nissim I, Sedensky MM, Yudko M, Morgan PG: Metabolic pathway profiling of mitochondrial respiratory chain mutants in C. elegans. Mol Genet Metab. 2008, 93: 388-397. 10.1016/j.ymgme.2007.11.007.View ArticlePubMedGoogle Scholar
  11. Ashrafi K, Chang FY, Watts JL, Fraser AG, Kamath RS, Ahringer J, Ruvkun G: Genome-wide RNAi analysis of Caenorhabditis elegans fat regulatory genes. Nature. 2003, 421: 268-272. 10.1038/nature01279.View ArticlePubMedGoogle Scholar
  12. Brock TJ, Browse J, Watts JL: Fatty acid desaturation and the regulation of adiposity in Caenorhabditis elegans. Genetics. 2007, 176: 865-875. 10.1534/genetics.107.071860.PubMed CentralView ArticlePubMedGoogle Scholar
  13. Mak HY, Nelson LS, Basson M, Johnson CD, Ruvkun G: Polygenic control of Caenorhabditis elegans fat storage. Nature Genetics. 2006, 38: 363-368. 10.1038/ng1739.View ArticlePubMedGoogle Scholar
  14. Mak HY, Ruvkun G: Intercellular signaling of reproductive development by the C. elegans DAF-9 cytochrome P450. Development. 2004, 131: 1777-1787. 10.1242/dev.01069.View ArticlePubMedGoogle Scholar
  15. Schroeder LK, Kremer S, Kramer MJ, Currie E, Kwan E, Watts JL, Lawrenson AL, Hermann GJ: Function of the Caenorhabditis elegans ABC transporter PGP-2 in the biogenesis of a lysosome-related fat storage organelle. Mol. Biol Cell. 2007, 18: 995-1008. 10.1091/mbc.E06-08-0685.PubMed CentralView ArticlePubMedGoogle Scholar
  16. Weaver TE, Na CL, Stahlman M: Biogenesis of lamellar bodies, lysosome-related organelles involved in storage and secretion of pulmonary surfactant. Semin Cell Dev. Biol. 2002, 13: 263-270. 10.1016/S1084952102000551.View ArticlePubMedGoogle Scholar
  17. Taubert S, Van Gilst MR, Hansen M, Yamamoto KR: A Mediator subunit, MDT-15, integratesregulation of fatty acid metabolism by NHR-49-dependent and-independent pathways in C. elegans. Genes Dev. 2006, 20: 1137-1149. 10.1101/gad.1395406.PubMed CentralView ArticlePubMedGoogle Scholar
  18. Wang YX, Lee CH, Tiep S, Yu RT, Ham J, Kang H, Evans RM: Peroxisome-proliferator-activated receptor delta activates fat metabolism to prevent obesity. Cell. 2003, 113: 159-170. 10.1016/S0092-8674(03)00269-1.View ArticlePubMedGoogle Scholar
  19. Desvergne B, Michalik L, Wahli W: Transcriptional regulation of metabolism. Physiol Rev. 2006, 86: 465-514. 10.1152/physrev.00025.2005.View ArticlePubMedGoogle Scholar
  20. Narbonne P, Roy R: Caenorhabditis elegans dauers need LKB1/AMPK to ration lipid reserves and ensure long-term survival. Nature. 2008, 457: 210-214. 10.1038/nature07536.View ArticlePubMedGoogle Scholar
  21. Wang MC, O'Rourke EJ, Ruvkun G: Fat metabolism links germline stem cells and longevity in C. elegans. Science. 2008, 322: 957-960. 10.1126/science.1162011.PubMed CentralView ArticlePubMedGoogle Scholar
  22. Mashek DG, Coleman RA: Cellular fatty acid uptake: the contribution of metabolism. Curr Opin Lipidol. 2006, 17: 274-278. 10.1097/01.mol.0000226119.20307.2b.View ArticlePubMedGoogle Scholar
  23. Larsen MK, Tuck S, Faergeman NJ, Knudsen J: MAA-1, a novel acyl-CoA-binding protein involved in endosomal vesicle transport in Caenorhabditis elegans. Mol Biol Cell. 2006, 17: 4318-4329. 10.1091/mbc.E06-01-0035.PubMed CentralView ArticlePubMedGoogle Scholar
  24. Resh MD: Trafficking and signaling by fatty-acylated and prenylated proteins. Nat Chem Biol. 2006, 2: 584-590. 10.1038/nchembio834.View ArticlePubMedGoogle Scholar
  25. Mukhopadhyay A, Deplancke B, Walhout JM, Tissenbaum HA: C. elegans tubby regulates life span and fat storage by two independent mechanisms. Cell Metab. 2005, 2: 35-42. 10.1016/j.cmet.2005.06.004.View ArticlePubMedGoogle Scholar
  26. Houthoofd K, Braeckman BP, Johnson TE, Vanfleteren JR: No reduction of metabolic rate in food restricted Caenorhabditis elegans. Exp Gerontol. 2002, 37: 1359-1369. 10.1016/S0531-5565(02)00172-9.View ArticlePubMedGoogle Scholar
  27. Ware RW, Crossland K, Russell RL, Clark DV: The nerve ring of the nematode C elegans: Sensory input and motor output. J Comp Neurol. 1975, 162: 71-110. 10.1002/cne.901620106.View ArticleGoogle Scholar
  28. Lewis JA, Hodgkin JA: Specific neuroanatomical changes in chemosensory mutants of the nematode Caenorhabditis elegans. J Comp Neurol. 1977, 172 (3): 489-510. 10.1002/cne.901720306.View ArticlePubMedGoogle Scholar
  29. Douglas SJ, Dawson-Scully K, Sokolowski MB: The neurogenetics and evolution of food-related behaviour. Trends Neurosci. 2005, 28 (12): 644-652.View ArticlePubMedGoogle Scholar

Copyright

© Lee et al; licensee BioMed Central Ltd. 2010

This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement

Journal of Biomedical Science

ISSN: 1423-0127